Project Grant R44AI179440
Award Date 9/1/23
Completion Date 8/31/26
Dollars Obligated $5M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- This $649,896 federal Project Grant awarded by the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) program supports the development and testing of an mRNA vaccine cocktail against influenza A viruses (IAV) in livestock. The project aims to create a universal influenza vaccine that can provide broad protection against diverse IAV strains, including highly pathogenic avian influenza (HPAI) H5N1...
- The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...
- The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...
- This Project Grant award, totaling $390,942.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of the project is to use self-assembled protein nanocages (SAPNs) as a universal flu vaccine platform to enhance the effectiveness of influenza vaccines. Specifically, the SAPNs will present multiple copies of three highly conserved influenza antigens: trimeric...
- This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...
- Flugen Inc. was awarded a $5.6 million Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of April 1, 2023 through March 31, 2026. The grant will support Flugen's work to develop scalable manufacturing and toxicity testing methods for an intranasal M2SR influenza vaccine. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- This federal Project Grant award of $454,278.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an adjuvanted intranasal influenza vaccine capable of generating lung-resident memory T cells to provide broadly cross-reactive and heterosubtypic immunity. The research project, conducted by the University of Kentucky Research Foundation, aims to characterize the T...